A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations

The factor VIII (FVIII)-neutralizing antibody (inhibitor) seen in 25%–30% of patients with severe haemophilia A (SHA). Vaccination is a non-genetic risk factor of inhibitor development as ‘danger signal’ which may provide a pro-inflammatory microenvironment to increase FVIII immunogenicity. We repor...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Immunopathol Pharmacol
Asıl Yazarlar: Li, Zekun, Chen, Zhenping, Cheng, Xiaoling, Wu, Xinyi, Li, Gang, Zhen, Yingzi, Poon, Man-Chiu, Wu, Runhui
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2020
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7338642/
https://ncbi.nlm.nih.gov/pubmed/32627611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2058738420934618
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller